AcelRx Pharmaceuticals, Inc. – NASDAQ:ACRX
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
AcelRx Pharmaceuticals stock price monthly change
+18.04%
month
AcelRx Pharmaceuticals stock price quarterly change
+28.45%
quarter
AcelRx Pharmaceuticals stock price yearly change
-62.28%
year
AcelRx Pharmaceuticals key metrics
Market Cap | 14.57M |
Enterprise value | 59.25K |
P/E | 0.12 |
EV/Sales | 0.02 |
EV/EBITDA | N/A |
Price/Sales | 1.76 |
Price/Book | 0.22 |
PEG ratio | N/A |
EPS | -1.00 |
Revenue | N/A |
EBITDA | -12.14M |
Income | -7.87M |
Revenue Q/Q | -76.92% |
Revenue Y/Y | -59.10% |
Profit margin | 3943.37% |
Oper. margin | -2127.24% |
Gross margin | -52.75% |
EBIT margin | -2127.24% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAcelRx Pharmaceuticals stock price history
AcelRx Pharmaceuticals stock forecast
AcelRx Pharmaceuticals financial statements
| Dec 2022 | 252K | -7.48M | -2969.84% |
|---|---|---|---|
| Mar 2023 | 0 | 5.33M | |
| Jun 2023 | 253K | -4.37M | -1727.67% |
| Sep 2023 | 117K | -1.35M | -1159.83% |
| 2025 | 2.50M | -22.24M | -888.7% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 47487000 | 25.67M | 54.06% |
|---|---|---|---|
| Mar 2023 | 26292000 | 12.05M | 45.83% |
| Jun 2023 | 17725000 | 7.30M | 41.22% |
| Sep 2023 | 23261000 | 4.95M | 21.3% |
| Dec 2022 | -5.41M | 2.66M | 5.29M |
|---|---|---|---|
| Mar 2023 | -5.25M | 400K | -2.07M |
| Jun 2023 | -5.33M | 2.72M | -3.33M |
| Sep 2023 | -2.96M | 0 | 8.93M |
AcelRx Pharmaceuticals alternative data
| Aug 2023 | 19 |
|---|---|
| Sep 2023 | 19 |
| Oct 2023 | 19 |
| Nov 2023 | 19 |
| Dec 2023 | 19 |
| Jan 2024 | 19 |
| Feb 2024 | 19 |
| Mar 2024 | 19 |
| Apr 2024 | 19 |
| May 2024 | 19 |
| Jun 2024 | 19 |
| Jul 2024 | 19 |
AcelRx Pharmaceuticals other data
42.33%
-21.77%
of ACRX is owned by hedge funds
44
-10
19.84M
-10.20M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 16956 |
| Sep 2023 | 10000 | 0 |
| Dec 2023 | 10000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ANGOTTI VINCENT J. director, officer.. | Common Stock | 10,000 | $0.73 | $7,270 | ||
Purchase | ANGOTTI VINCENT J. director, officer.. | Common Stock | 10,000 | $0.8 | $7,950 | ||
Sale | PALMER PAMELA P director, officer.. | Common Stock | 7,442 | $1.09 | $8,104 | ||
Sale | PALMER PAMELA P director, officer.. | Common Stock | 9,514 | $1.17 | $11,131 | ||
Purchase | ANGOTTI VINCENT J. director, officer.. | Common Stock | 46,400 | $0.22 | $10,347 | ||
Purchase | ANGOTTI VINCENT J. director, officer.. | Common Stock | 7,547 | $1.33 | $10,038 | ||
Purchase | ADAMS ADRIAN director | Common Stock | 100,000 | $1.29 | $128,900 | ||
Purchase | EDWARDS MARK G director | Common Stock | 25,000 | $1.78 | $44,575 | ||
Purchase | ANGOTTI VINCENT J. director, officer.. | Common Stock | 8,379 | $1.79 | $14,973 | ||
Purchase | EDWARDS MARK G director | Common Stock | 5,000 | $2.17 | $10,850 |
| Patent |
|---|
Grant Filling date: 22 Dec 2015 Issue date: 13 Jul 2021 |
Application Filling date: 15 Jan 2021 Issue date: 20 May 2021 |
Grant Filling date: 26 Sep 2018 Issue date: 19 Jan 2021 |
Grant Filling date: 8 May 2017 Issue date: 14 Jul 2020 |
Application Filling date: 9 Jan 2019 Issue date: 23 Jan 2020 |
Grant Filling date: 5 Oct 2018 Issue date: 17 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 10 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 30 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Vincent J. Angotti (1968) Chief Executive Officer & Director | $932,470 |
| Dr. Pamela Pierce Palmer (1963) Co-Founder, Chief Medical Officer & Director | $675,760 |
| Mr. Raffi Mark Asadorian (1969) Chief Financial Officer | $604,360 |
Mr. Anil N. Dasu (1963) Chief Engineering Officer | $478,090 |
AcelRx Pharmaceuticals: The Fog Is Getting Thicker
AcelRx: Battered And Bruised But Ready For Recovery In 2022
AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm
AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
AcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-Reward
Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles
-
When is AcelRx Pharmaceuticals's next earnings date?
Unfortunately, AcelRx Pharmaceuticals's (ACRX) next earnings date is currently unknown.
-
Does AcelRx Pharmaceuticals pay dividends?
No, AcelRx Pharmaceuticals does not pay dividends.
-
How much money does AcelRx Pharmaceuticals make?
AcelRx Pharmaceuticals has a market capitalization of 14.57M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 63.24% to 651K US dollars.
-
What is AcelRx Pharmaceuticals's stock symbol?
AcelRx Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ACRX".
-
What is AcelRx Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of AcelRx Pharmaceuticals?
Shares of AcelRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AcelRx Pharmaceuticals's key executives?
AcelRx Pharmaceuticals's management team includes the following people:
- Mr. Vincent J. Angotti Chief Executive Officer & Director(age: 57, pay: $932,470)
- Dr. Pamela Pierce Palmer Co-Founder, Chief Medical Officer & Director(age: 62, pay: $675,760)
- Mr. Raffi Mark Asadorian Chief Financial Officer(age: 56, pay: $604,360)
- Mr. Anil N. Dasu Chief Engineering Officer(age: 62, pay: $478,090)
-
Is AcelRx Pharmaceuticals founder-led company?
Yes, AcelRx Pharmaceuticals is a company led by its founder Dr. Pamela Pierce Palmer.
-
How many employees does AcelRx Pharmaceuticals have?
As Jul 2024, AcelRx Pharmaceuticals employs 19 workers.
-
When AcelRx Pharmaceuticals went public?
AcelRx Pharmaceuticals, Inc. is publicly traded company for more then 14 years since IPO on 11 Feb 2011.
-
What is AcelRx Pharmaceuticals's official website?
The official website for AcelRx Pharmaceuticals is acelrx.com.
-
Where are AcelRx Pharmaceuticals's headquarters?
AcelRx Pharmaceuticals is headquartered at 25821 Industrial Boulevard, Hayward, CA.
-
How can i contact AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals's mailing address is 25821 Industrial Boulevard, Hayward, CA and company can be reached via phone at +65 02163500.
AcelRx Pharmaceuticals company profile:
AcelRx Pharmaceuticals, Inc.
acelrx.comExchange:
NASDAQ
Full time employees:
19
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
25821 Industrial Boulevard
Hayward, CA 94545
Hayward, CA 94545
CIK: 0001427925
ISIN: US00444T2096
CUSIP: 00444T100
